Altimmune Inc
NASDAQ:ALT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Altimmune Inc
NASDAQ:ALT
|
US |
|
CTO Realty Growth Inc
NYSE:CTO
|
US |
|
Volvo AB
OTC:VOLVF
|
SE |
|
MercadoLibre Inc
BMV:MELIN
|
UY |
|
Barings BDC Inc
NYSE:BBDC
|
US |
|
G
|
GM Leather SpA
MIL:GML
|
IT |
|
NextNav Inc
NASDAQ:NN
|
US |
|
H
|
Hermes International SCA
XMUN:HMI
|
FR |
|
ConvaTec Group PLC
LSE:CTEC
|
UK |
|
J
|
Jbs NV
NYSE:JBS
|
NL |
|
Equifax Inc
NYSE:EFX
|
US |
|
Molson Coors Beverage Co
NYSE:TAP
|
US |
|
T
|
Truworths International Ltd
JSE:TRU
|
ZA |
|
S
|
Schoeller Bleckmann Oilfield Equipment AG
VSE:SBO
|
AT |
|
G
|
Goodfellow Inc
OTC:GFELF
|
CA |
|
Novartis AG
F:NOTA
|
CH |
|
Bayan Resources Tbk PT
F:BNB
|
ID |
Wall St Price Targets
ALT Price Targets Summary
Altimmune Inc
According to Wall Street analysts, the average 1-year price target for
ALT is 19.58 USD with a low forecast of 1.01 USD and a high forecast of 29.4 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ALT's stock price target?
Price Target
19.58
USD
According to Wall Street analysts, the average 1-year price target for
ALT is 19.58 USD with a low forecast of 1.01 USD and a high forecast of 29.4 USD.
What is the Revenue forecast for Altimmune Inc?
Projected CAGR
276%
Over the last 14 years, the compound annual growth rate for Revenue has been -37%. The projected CAGR for the next 8 years is 276%.